Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

Blood

Volumn 101, Issue 7, 2003, Pages 2507-2513

  Manshouri, Taghi ^b   Do, Kim Anh ^b   Wang, Xuemei ^b   Giles, Francis J ^b   O'Brien, Susan M ^b   Saffer, Helen ^b   Thomas, Deborah ^b   Jilani, Iman ^b   Kantarjian, Hagop M ^b   Keating, Michael J ^b   Albitar, Maher ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD20 ANTIGEN; CD38 ANTIGEN; HEMOGLOBIN; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; THROMBOCYTE COUNT; ANTIGEN ANTIBODY REACTION; BINDING COMPETITION; BLOOD; CASE CONTROL STUDY; IMMUNOASSAY; IMMUNOLOGY; MORTALITY; SURVIVAL; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD20; BINDING, COMPETITIVE; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0038446696     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1639     Document Type: Article

References (38)

1. Tedder TF, Schlossman SF. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B-lymphocytes. J Biol Chem. 1988;263:10009-10015.
2. Warzynski MJ, Graham DM, Axtell RA, Zakem MH, Rotman RK. Low level CD20 expression on T cell malignancies. Cytometry. 1994;18:88-92.
3. Algino KM, Thomason RW, King DE, Montiel MM, Craig FE. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol. 1996;106:78-81.
4. Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol. 1985;35:3795-3801.
5. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B-lymphocytes. Immunol Today. 1994;15:450-454.
6. Kehrl JH, Riva A, Wilson GL, Thevenin C. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today. 1994;15:432-436.
7. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27:17-24.
8. Galiegue-Zouitina S, Collyn-d'Hooghe M, Denis C, et al. Molecular cloning of a t(11;14)(q13;q32) translocation breakpoint centromeric to the BCL1-MTC. Genes Chromosomes Cancer. 1994;11:246-255.
9. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem. 1995;270:22632-22638.
10. Popoff IJ, Savage JA, Blake J, Johnson P, Deans JP. The association between CD20 and Src-family tyrosine kinases requires an additional factor. Mol Immunol. 1998;35:207-214.
11. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000;26:133-143.
12. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low-density detergent-insoluble membrane compartment. J Biol Chem. 1998;273:344-348.
13. Marti GE, Faguet G, Bertin P, et al. CD20 and CD5 expression in B-chronic lymphocytic leukemia. Ann N Y Acad Sci. 1992;651:480-483.
14. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992;40:259-263.
15. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukemias. J Clin Pathol. 1998;51:364-369.
16. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol. 1999;26:74-78.
17. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214-226.
18. Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S, Tura S. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol. 2000;18:3875-3877.
19. Hainsworth JD. Rituximab as first-line systemic therapy for patients with low-grade lymphoma. Semin Oncol. 2000;27:25-29.
20. Keating M, O'Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol. 2000;27:86-90.
21. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000;27:37-41.
22. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
23. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;60:163-170.
26. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829-836.
27. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
28. Therneau TM, E. Atkinson E, An introduction to recursive partitioning using the RPART routine. Technical report. Rochester, MN Mayo Foundation: 1997.
29. Becker RA, Chambers JM, Wilks AR. The New S Language. Pacific Grove, CA: Wadsworth; 1988.
30. Therneau TM, Grambsch PM, Fleming TR. Martingale based residuals for survival models. Biometrika. 1990;77:147-160.
31. Pleskova I, Sedlak J, Duraj J, et al. Monoclonal antibody directed to MHC class I antigen (Bra23/ 9): characterization and utilization for study of antigen expression in differentiation of U 937 cell line. Neoplasma. 1988;35:657-664.
32. Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem. 2002;48:1186-1193.
33. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26:69-76.
34. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1 H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001;41:77-87.
35. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol. 2000;12:574-581.
36. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97:3197-3204.
37. Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res. 2000;6:2363-2370.
38. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.